INTERNATIONAL MATCHMAKING SYMPOSIUM ADTCA 2024 on 20/21 June

Search for:

Home » _News » Smart Innovations » Page 10

AMR news related to Smart Innovations

For Scientists, Researchers and Innovating Professionals who want to stay adequately informed on Antimicrobial resistance, AMR Insights offers the most comprehensive overview of recently published, global news and information.

CARB-X IS FUNDING UK-BIOTECH GENOMEKEY TO DEVELOP A RAPID DIAGNOSTIC FOR SEPSIS, A LEADING CAUSE OF DEATH IN HOSPITALS

Lack of Funding Drives Biotech to Suspend Drug-Resistant Antibiotic Pipeline

“We Don’t Just Need a Few New Antibiotics, We Need an Arsenal”

Antibiotic development, stewardship advocates see window of opportunity

2020 antibacterial agents in clinical and preclinical development: an overview and analysis

CARB-X IS FUNDING PHICO THERAPEUTICS TO DEVELOP AN ENGINEERED BACTERIOPHAGE DRUG TO TREAT VENTILATOR-ASSOCIATED PNEUMONIA CAUSED BY DRUG-RESISTANT PSEUDOMONAS AERUGINOSA

BioVersys receives €20 million in EU financing to support development of new antibiotics

Superbug killer: New nanotech destroys bacteria and fungal cells

JPIAMR project dashboard published

CARB-X IS FUNDING NOVEL MICRODEVICES TO DEVELOP A RAPID AND PORTABLE DIAGNOSTIC FOR SEXUALLY TRANSMITTED DISEASES INCLUDING ANTIBIOTIC-RESISTANT INFECTIONS

From Treatment Options to Precision Medicine: The Future of “Omics-Based” Antibiotic Resistance Surveillance Data

Culture-Independent Genotyping, Virulence and Antimicrobial Resistance Gene Identification of Staphylococcus aureus from Orthopaedic Implant-Associated Infections

New ReAct report: Governments need to take more leadership to ensure global sustainable access to effective antibiotics

Oxford vaccine team wins £1.4m to develop jab against ‘super gonorrhoea’

Now Britain’s genome-busters use Covid success to target superbugs

Groups urge Congress to boost funding for AMR, antibiotic development

Leveraging Marine Natural Products as a Platform to Tackle Bacterial Resistance and Persistence

Indian Priority Pathogen List jointly developed by DBT and WHO India Office

Practical nanozymes discovered to fight antimicrobial resistance

Facile accelerated specific therapeutic (FAST) platform develops antisense therapies to counter multidrug-resistant bacteria

NIH awards grants to support bacteriophage therapy research

Chemically modified and conjugated antimicrobial peptides against superbugs

New model can predict how bacteria develop antibiotic resistance

Antibiotics Currently in Global Clinical Development (update)

AMR Fund and Global Cohorts Working to Prevent Another Pandemic

Synergistic effect of antimicrobial peptide LL-37 and colistin combination against multidrug-resistant Escherichia coli isolates

Accelerated antimicrobial discovery via deep generative models and molecular dynamics simulations

Identification of Antimicrobial Resistance Mechanism May Lead to Novel Drug Targets

AMR research in a post-pandemic world: Insights on antimicrobial resistance research in the COVID-19 pandemic

Looking for Solutions to the Pitfalls of Developing Novel Antibacterials in an Economically Challenging System

Tracking the Pipeline of Antibiotics in Development

CARB-X IS FUNDING AFFINIVAX TO DEVELOP A NOVEL VACCINE TO PREVENT STAPHYLOCOCCUS AUREUS BACTERIAL INFECTIONS

Research pinpoints unique drug target in antibiotic resistant bacteria

Reducing antibiotic prescribing with rapid POC respiratory infection test

Resistance is rarely futile – reinvigorating the AMR ecosystem

New collaboration between PAR Foundation and the Global AMR R&D Hub

Malaria data opened up to combat drug resistance

Antibiotic Development Needs Economic Incentives

Understanding the Antibacterial Resistance: Computational Explorations in Bacterial Membranes

25 February 2021

Monitoring the Bacterial Response to Antibiotic and Time Growth Using Near-infrared Spectroscopy Combined with Machine Learning

25 February 2021

Engineered viruses can fight the rise of antibiotic-resistant bacteria

25 February 2021

AI-based mobile application to fight antibiotic resistance

24 February 2021

To Push or To Pull? In a Post-COVID World, Supporting and Incentivizing Antimicrobial Drug Development Must Become a Governmental Priority

24 February 2021

CARB-X IS FUNDING THE UNIVERSITY OF QUEENSLAND TO DEVELOP A NEW DRUG TARGETED TO LOW- AND MIDDLE-INCOME COUNTRIES

23 February 2021

X-factor to help antibiotics regain their spark

18 February 2021

Global Principles on Incentivizing Antibiotic R&D

18 February 2021

The AMR Action Fund announces its first non-industry investments, raising an additional US$140 million toward addressing antimicrobial resistance (AMR)

18 February 2021

The AMR Action Fund announces appointment of CEO, Henry B. Skinner, PhD

17 February 2021

Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ for the Treatment of Prosthetic Joint Infections

13 February 2021

GARDP welcomes additional funding from UK to develop new treatment for gonorrhoea

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed